NCT05361395 2026-03-03
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Phase 1 Active not recruiting
Clinical Trials
12 trialsNCT06745323 2026-03-03
DeLLphi-309
Amgen
Phase 2 Active not recruiting
NCT06117774 2026-02-27
DeLLphi-306
Amgen
Phase 3 Recruiting
NCT07005128 2026-02-27
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT07037758 2026-02-20
DeLLphi-311
Amgen
Phase 1 Recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT06211036 2025-12-17
DeLLphi-305
Amgen
Phase 3 Active not recruiting
NCT06598306 2025-12-01
DeLLphi-308
Amgen
Phase 1 Recruiting
NCT06502977 2025-10-28
DeLLphi-307
Amgen
Phase 2 Active not recruiting
NCT04885998 2025-09-29
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Amgen
Phase 1 Completed
NCT04702737 2025-09-12
DeLLpro-300
Amgen
Phase 1 Completed
NCT06064500 2025-03-10
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Amgen
Approved for marketing